Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Developing a multi-modal neuroimaging-based BrainAge model across childhood.

bioRxiv : the preprint server for biology·2026
Same author

Positive and negative maternal mental health demonstrate distinct pathways to childhood depression.

Psychological medicine·2026
Same author

Breastfeeding duration and bone mineral density in childhood: a prospective study within the Growing Up in Singapore Toward healthy Outcomes (GUSTO) cohort.

The American journal of clinical nutrition·2026
Same author

A longitudinal study of chronotype stability from preschool-to school-age and its association with sleep problems.

Sleep medicine·2026
Same author

Maternal-prenatal gut microbiome-systemic metabolome perturbations and T<sub>H</sub>2-skewed immunity link to offspring gut microbiome disruption and atopic dermatitis susceptibility.

Genome medicine·2026
Same author

Associations Among Physical Activity, Leukocyte Telomere Length, and Depression in Pregnancy: A Cohort Study.

Women's health issues : official publication of the Jacobs Institute of Women's Health·2026

Related Experiment Video

Updated: Jun 16, 2026

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

Progestational agents for treating threatened or established preterm labour.

Lin-Lin Su1, Miny Samuel, Yap-Seng Chong

  • 1Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, National University Hospital, 5 Lower Kent Ridge Wing, Singapore, Singapore, 119074.

The Cochrane Database of Systematic Reviews
|January 22, 2010
PubMed
Summary

Progestational agents may reduce preterm birth and uterine contractions, but evidence is limited. More research is needed to confirm their effectiveness for threatened preterm labor.

Related Experiment Videos

Last Updated: Jun 16, 2026

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

Area of Science:

  • Obstetrics and Gynecology
  • Perinatal Medicine
  • Pharmacology

Background:

  • Preterm birth is a significant cause of perinatal complications and mortality globally.
  • Existing tocolytic agents have shown limited efficacy in prolonging gestation or improving neonatal outcomes.
  • Progesterone plays a crucial role in maintaining pregnancy by inhibiting uterine contractility.

Purpose of the Study:

  • To evaluate the effectiveness of progestational agents in treating threatened or established preterm labor.
  • To assess progestational agents as a sole treatment or in conjunction with other tocolytics for preterm labor.
  • To determine efficacy in women with intact membranes.

Main Methods:

  • Comprehensive literature search of major databases (Cochrane, MEDLINE, EMBASE) up to January 2009.
  • Inclusion of randomized controlled trials comparing progestational agents with placebo, other tocolytics, or no treatment.
  • Independent data extraction and quality assessment by two reviewers.

Main Results:

  • Preliminary data suggest progestational agents may reduce deliveries before 37 weeks gestation.
  • Potential benefits include attenuating cervical shortening and decreasing uterine contraction frequency.
  • The meta-analysis was limited by a small number of studies and participants (35-60 per study).

Conclusions:

  • Insufficient evidence currently supports the routine use of progestational agents for preterm labor.
  • Further high-quality research is required to establish their role in managing preterm birth.
  • The current data do not allow for definitive recommendations regarding progestational agents as tocolytics.